Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4291 to 4305 of 9037 results

  1. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  2. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (HTG714)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

  3. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  4. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (HTG375)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.

  5. Single‑incision laparoscopic cholecystectomy (HTG361)

    Evidence-based recommendations on single incision laparoscopic cholecystectomy. This involves removing the gallbladder through a small cut, most often below the bellly button.

  6. Minimally invasive video‑assisted parathyroidectomy (HTG350)

    Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.

  7. Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia (HTG345)

    Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.

  8. Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (HTG319)

    Evidence-based recommendations on photochemical corneal cross linkage using riboflavin and ultraviolet A for keratoconus. This involves using special eye drops and exposing the eye ultraviolet light, with the aim to strengthen the cornea.

  9. Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)

    Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.

  10. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)

    Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

  11. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.

  12. Why address health inequalities?

    Health inequalities can be experienced by people grouped by a range of different factors.

  13. Patient decision aids

    Home Implementing NICE guidance...

  14. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  15. Prioritisation board decisions 2026

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.